Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-81

Isn't bis+dox synergistic in efficacy i.e. the efficacy of the combination is greater than the sum of the two individual efficacies? Or am I mis-remembering previous data?

If that was the case then it make sense to pursue a combination trial first anyway and possibly leave single agent studies for the future when physician's clinical experience with bisantrene is more established?

Most of the current oncology treatment paradigm is predicated upon combination therapies given its benefit in overcoming resistance so this also makes sense to me as well. At least potentially partially explains clinician reluctance to engage in single-agent studies.